Partner With Us
Denovicon’s generative AI-physics platform searches a trillion-molecule space for molecules that are already druglike. You start with lead-ready molecules, not hits that require years of refinement. The result: better candidates, faster timelines, and dramatically reduced costs.
Generative AI Multi-Objective optimization
Our AI-physics platform uses a proprietary multi-objective optimization workflow to design molecules optimized for druglikeness from the start – not sequentially filtered afterward. Every output balances potency, selectivity, ADMET properties, and synthetic accessibility in a single unified search.
Improved Synthesizability
Unlike other generative models that produce molecules you often can’t synthesize, our platform optimizes for synthesizability from the start.
Complete Interpretability
Every optimization decision maps to real chemical features and their interactions. You get genuine structure-activity/property relationships, not the usual black-box predictions. This enables stronger medicinal chemistry decision-making.
Validated Results
Denovicon doesn’t just help others with their therapeutic projects; we maintain our own internal pipeline, and the platform has been validated both internally and externally.
Our PARP7 Inhibitors:
✅ Potent and selective (DNT-1569: PARP7/1/2 = 4 nM/8 μM/10 μM)
✅ Improved profile compared to clinical compound (RBN-2397: PARP7/1/2 = 3 nM/37 nM/17 nM)
✅ Virtual design < 2 days!
✅ Novel chemical matter (Tanimoto similarity to RBN-2397 = 0.14)
Ready to Discuss?
For partnership inquiries:
Zoey Pan
Head of Strategy & External Collaborations
zoey@denovicontx.com